Search
for
Sort by
Research 901–930 of 1000+
- Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss
- Lasers for Dermatology and Skin Biology
- The evolution of healthy skin to acne lesions: a longitudinal, <i>in vivo</i> evaluation with reflectance confocal microscopy and optical coherence tomography
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution?
- Probiotics in Dermatology: An Evidence-based Approach
- Response of alopecia areata of the beard to oral tofacitinib
- Clinical and microscopic evaluation of long-term (6 months) epilation effects of the ipulse personal home-use intense pulsed light (IPL) device
- A Gender Hypothesis of sex disparities in adverse drug events
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
- Colored dots on trichoscopy—beware of artifacts
- Exploring Pediatric Dermatology in Skin of Color: Focus on Dermoscopy
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review
- Rapid onset of action of minoxidil 5% topical solution in a 4-month German observational study on both patients and physicians
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Ketoconazole shampoo-induced hair discoloration,
- Case reports and anecdotal evidence
- Calcipotriene plus betamethasone dipropionate gel: a new combination therapy for scalp psoriasis
- Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial
- Laser-based interventions for scarring alopecia: a meta-analytic review of clinical outcomes
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Unique Dermatological and Systemic Manifestations in a Classic Pediatric Case of Kindler Syndrome: A Case Report and Literature Review
- Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
- Comparative analysis of temperature‐controlled cryotherapy versus intralesional triamcinolone acetonide injection for alopecia areata: An intrasubject split‐lesion pilot study